Seres Therapeutics (NASDAQ:MCRB) Upgraded at Zacks Research

Seres Therapeutics (NASDAQ:MCRB) was upgraded by research analysts at Zacks Research to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Several other brokerages have also recently weighed in on MCRB. Weiss Ratings cut shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Wall Street Zen upgraded shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. HC Wainwright initiated coverage on Seres Therapeutics in a report on Tuesday. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Canaccord Genuity Group restated a “buy” rating and set a $22.00 price target on shares of Seres Therapeutics in a research report on Friday, March 13th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Seres Therapeutics Stock Performance

MCRB opened at $6.83 on Tuesday. The firm’s 50-day simple moving average is $7.43 and its 200-day simple moving average is $10.59. Seres Therapeutics has a twelve month low of $5.31 and a twelve month high of $29.98. The firm has a market cap of $66.07 million, a price-to-earnings ratio of -1.32 and a beta of 0.13.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.88) by ($0.20). The company had revenue of $0.36 million for the quarter, compared to analyst estimates of $0.36 million. As a group, sell-side analysts anticipate that Seres Therapeutics will post -5.84 EPS for the current fiscal year.

Institutional Trading of Seres Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Seres Therapeutics by 6.8% during the 3rd quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock valued at $6,001,000 after purchasing an additional 19,793 shares during the period. Invesco Ltd. grew its position in shares of Seres Therapeutics by 193.2% during the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock worth $96,000 after buying an additional 89,995 shares during the period. Vontobel Holding Ltd. raised its stake in shares of Seres Therapeutics by 4.8% during the fourth quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock worth $1,536,000 after buying an additional 4,723 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Seres Therapeutics during the second quarter worth approximately $1,016,000. Finally, Geode Capital Management LLC lifted its holdings in Seres Therapeutics by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock valued at $1,282,000 after buying an additional 1,160 shares during the period. 59.34% of the stock is owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.